SAB Biotherapeutics Inc - Warrant — Financial Statements (NASDAQ:SABSW)

Financials

Total revenue —60.88 M23.9 M2.24 M1.32 M 283.28 K Gross profit —60.88 M23.9 M2.24 M1.32 M 283.28 K Operating expenses —74.27 M52.82 M40.31 M44.23 M 43.31 M Selling/general/admin expenses —17.09 M16.38 M23.8 M13.98 M 12.23 M Research & development —57.18 M36.44 M16.52 M30.25 M 31.08 M Operating income —-13.39 M-28.92 M-38.08 M-42.91 M -43.19 M Non-Operating Income, Total —5 48810.2 M-4.12 M8.81 M 61.93 M Interest expense, net of interest capitalized —294.46 K301.58 K315.28 K318.4 K 248.08 K Non-Operating Income, excl. Interest Expenses —-294.46 K9.87 M-4.87 M6.03 M 59.22 M Unusual income/expense —5 48833.75 K435.09 K2.45 M 2.46 M Pretax income —-17.14 M-18.72 M-42.19 M-34.42 M 18.49 M Equity in earnings ————— — Taxes —025.63 K00 -5.97 M Non-controlling/minority interest ————— — After tax other income/expense ————— — Net income before discontinued operations —-17.14 M-18.74 M-42.19 M-34.11 M 18.74 M Discontinued operations ————— — Net income —-17.14 M-18.74 M-42.19 M-34.11 M 18.74 M Dilution adjustment ————— — Preferred dividends ————— — Diluted net income available to common stockholders —-17.14 M-18.74 M-42.19 M-34.11 M -43.26 M Basic earnings per share (Basic EPS) —-6.3-4.3-7.64-3.68 -2.38 Diluted earnings per share (Diluted EPS) —-6.3-4.31-7.64-3.68 -3.09 Average basic shares outstanding —2.73 M4.35 M5.52 M9.26 M 38.51 M Diluted shares outstanding —2.73 M4.35 M5.52 M9.26 M 105.71 M EBITDA ————— — EBIT ————— — Cost of revenue ————— — Other cost of goods sold ————— — Depreciation & amortization (cash flow) —1.49 M3.17 M3.7 M4.7 M 3.1 M